HDAC9 and sialidosis: Based on these findings, we wanted to test the effect of another Food and Drug Administration (FDA)-approved HDAC inhibitor, romidepsin, that targets more specifically class I HDAC [20,21,22], on all 12 type I sialidosis fibroblasts included in this study.